Characteristics of patients at baseline
| Characteristic (n = 39) . | Value . |
|---|---|
| Median age, y (range) | 71 (54-88) |
| Sex, M/F, n | 30/9 |
| CMML-1/2, n | 17/22 |
| Abnormal karyotype, n (%) | 18 (46) |
| Splenomegaly > 5 cm, n (%) | 15 (38) |
| Extramedullary disease, n (%) | 8 (21) |
| Prior treatment with hydroxyurea, n (%) | 16 (41) |
| Median WBC, g/L (range) | 20.9 (4.1-147.3) |
| Median peripheral blood monocytes, g/L (range) | 4.8 (1.0-95.7) |
| Median Proportion of immature granulocytes, % (range) | 35 (0-84) |
| Median Hb level, g/dL (range) | 9.3 (1-14) |
| Median bone marrow blasts, % (range) | 10 (0-29) |
| Median platelet number, g/L (range) | 81 (12-560) |
| ASXL1, n mutated/n studied, % | 19/38 (50) |
| TET2, n mutated/n studied, % | 13/38 (34) |
| AML1, n mutated/n studied, % | 10/38 (26) |
| NRAS, n mutated/n studied, % | 6/38 (16) |
| KRAS, n mutated/n studied, % | 5/38 (13) |
| CBL, n mutated/n studied, % | 5/38 (13) |
| FLT3, n mutated/n studied, % | 3/38 (8) |
| JAK2, n mutated/n studied, % | 1/38 (3) |
| No mutation in the 8 screened genes, % | 4/38 (10) |
| Characteristic (n = 39) . | Value . |
|---|---|
| Median age, y (range) | 71 (54-88) |
| Sex, M/F, n | 30/9 |
| CMML-1/2, n | 17/22 |
| Abnormal karyotype, n (%) | 18 (46) |
| Splenomegaly > 5 cm, n (%) | 15 (38) |
| Extramedullary disease, n (%) | 8 (21) |
| Prior treatment with hydroxyurea, n (%) | 16 (41) |
| Median WBC, g/L (range) | 20.9 (4.1-147.3) |
| Median peripheral blood monocytes, g/L (range) | 4.8 (1.0-95.7) |
| Median Proportion of immature granulocytes, % (range) | 35 (0-84) |
| Median Hb level, g/dL (range) | 9.3 (1-14) |
| Median bone marrow blasts, % (range) | 10 (0-29) |
| Median platelet number, g/L (range) | 81 (12-560) |
| ASXL1, n mutated/n studied, % | 19/38 (50) |
| TET2, n mutated/n studied, % | 13/38 (34) |
| AML1, n mutated/n studied, % | 10/38 (26) |
| NRAS, n mutated/n studied, % | 6/38 (16) |
| KRAS, n mutated/n studied, % | 5/38 (13) |
| CBL, n mutated/n studied, % | 5/38 (13) |
| FLT3, n mutated/n studied, % | 3/38 (8) |
| JAK2, n mutated/n studied, % | 1/38 (3) |
| No mutation in the 8 screened genes, % | 4/38 (10) |